Zilucoplan
Also known as: Zilbrysq, RA101495, UCB7665
Zilucoplan is a complement C5 inhibitor peptide that blocks complement activation, preventing tissue damage in autoimmune and inflammatory conditions. This synthetic macrocyclic peptide specifically targets the C5 protein to halt the complement cascade.
Zilucoplan is a 3,407 Da research peptide. Zilucoplan is a complement C5 inhibitor peptide that blocks complement activation, preventing tissue damage in autoimmune and inflammatory conditions. This synthetic macrocyclic peptide specifically targets the C5 protein to halt the complement cascade.
Also called: Zilbrysq, RA101495, UCB7665
3,407
Molecular Weight
Daltons
2
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
0.3-0.6
Typical Dose
mg/kg
Overview
Zilucoplan represents a targeted approach to complement system modulation through selective C5 inhibition. The peptide binds to complement protein C5 with high affinity, preventing its cleavage into C5a and C5b fragments. This action stops formation of the membrane attack complex (MAC), which causes cell lysis and tissue damage in complement-mediated diseases. The macrocyclic structure provides enhanced stability and binding specificity compared to linear peptides. Research applications focus on myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and other complement-driven pathologies. The peptide's mechanism offers advantages over monoclonal antibodies through improved tissue penetration and subcutaneous administration compatibility.
Key Takeaways: Zilucoplan
- Strongest evidence supports Zilucoplan for myasthenia gravis symptom improvement and reduced inflammatory markers
- Research doses typically range from 0.3 to 0.6 mg/kg via subcutaneous
- 2 benefits with strong evidence, 2 moderate, 2 preliminary
- Half-life: 15-30 hours
- 4 cited research studies in this guide
Mechanism of Action
Zilucoplan functions as a selective complement C5 inhibitor by binding to the beta-chain of C5 protein. This binding prevents C5 convertase-mediated cleavage, blocking generation of C5a anaphylatoxin and C5b initiation of the membrane attack complex. The peptide's macrocyclic structure allows tight binding to the C5 cleavage site through multiple contact points. By halting complement activation at the C5 level, terminal complement effector functions are eliminated while preserving upstream complement functions like opsonization. This targeted inhibition reduces inflammation, prevents complement-mediated cell lysis, and protects tissues from immune attack.
Research Benefits
Zilucoplan at a Glance
Zilucoplan functions as a selective complement C5 inhibitor by binding to the beta-chain of C5 protein.
Myasthenia Gravis Symptom Improvement
Strong EvidenceBlocks complement-mediated destruction of acetylcholine receptors at neuromuscular junctions, reducing muscle weakness and fatigue in generalized myasthenia gravis patients.
Reduced Inflammatory Markers
Strong EvidenceDecreases C5a-mediated neutrophil activation and pro-inflammatory cytokine release, lowering systemic inflammation markers like CRP and IL-6.
Paroxysmal Nocturnal Hemoglobinuria Management
Moderate EvidencePrevents complement-mediated hemolysis of red blood cells lacking protective proteins, reducing anemia and hemoglobinuria episodes.
Improved Quality of Life Scores
Moderate EvidenceEnhances functional capacity and reduces disease burden in complement-mediated disorders, as measured by standardized quality of life assessments.
Neuroprotective Effects
PreliminaryShields neurons from complement-mediated damage in neuroinflammatory conditions by preventing membrane attack complex formation on neural tissue.
Reduced Steroid Dependency
PreliminaryAllows tapering of corticosteroid doses in autoimmune conditions by providing targeted complement inhibition without broad immunosuppression.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Myasthenia gravis research | 0.3–0.6 mg/kg | subcutaneous |
| PNH investigation | 15–30 mg | subcutaneous |
| Complement system studies | 0.1–0.5 mg/kg | subcutaneous |
Frequency
Daily or every other day
Timing
Consistent timing preferred, can be taken with or without food
Cycle Length
Continuous therapy in research protocols, typically 12-24 weeks for efficacy studies
Research Notes
- 1Requires gradual dose escalation in initial studies
- 2Monitor complement activity levels (CH50, AH50) during research
- 3Subcutaneous injection preferred over intravenous administration
- 4Research protocols often include loading doses for faster onset
Reconstitution Guide
Standard Reconstitution
Vial Size
50 mg
Bacteriostatic Water
1 mL
Concentration
500 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Zilucoplan vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 24 months unopened, 28 days after reconstitution when refrigerated.
Storage Temperature
2-8°C
Shelf Life
24 months unopened, 28 days after reconstitution when refrigerated
Important Notes
- •Use sterile water for injection or bacteriostatic water
- •Allow vial to reach room temperature before reconstitution
- •Gently swirl, do not shake vigorously to avoid foaming
- •Clear to slightly opalescent solution when properly reconstituted
- •Single-use vials recommended for research applications
Zilucoplan Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Zilucoplan Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (redness, swelling, pain)
- !Increased infection susceptibility, particularly encapsulated bacteria
- !Headache and fatigue
- !Upper respiratory tract infections
- !Gastrointestinal upset (nausea, diarrhea)
- !Muscle pain and arthralgia
- !Elevated liver enzymes (transient)
- !Hypersensitivity reactions (rare but serious)
- !Meningococcal infection risk (requires vaccination)
- !Complement-mediated disease flares upon discontinuation
Potential Interactions
- ⚡Live vaccines (increased infection risk, avoid concurrent use)
- ⚡Immunosuppressive medications (additive infection risk)
- ⚡Eculizumab or other complement inhibitors (redundant mechanisms)
- ⚡Anticoagulants (potential bleeding risk with thrombocytopenia)
- ⚡Rituximab and other B-cell depleting agents (enhanced immunosuppression)
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and Safety of Zilucoplan in Patients with Generalized Myasthenia Gravis
Phase 3 randomized controlled trial demonstrated significant improvement in MG-ADL scores and reduced rescue therapy need in 174 patients with generalized myasthenia gravis.
Complement C5 Inhibition with Zilucoplan in Immune-Mediated Necrotizing Myopathy
Case series showing potential benefits in complement-mediated muscle diseases, with improved strength scores and reduced inflammatory markers in 8 patients.
Pharmacokinetics and Pharmacodynamics of Zilucoplan in Healthy Volunteers
First-in-human study establishing dose-response relationships, demonstrating complete C5 inhibition at doses above 0.3 mg/kg with favorable safety profile.
Zilucoplan Treatment in Paroxysmal Nocturnal Hemoglobinuria: Pilot Study Results
Open-label pilot study in 15 PNH patients showed reduced hemolysis markers and improved hemoglobin levels with daily subcutaneous dosing.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Complement inhibition occurs within hours of administration, but clinical improvement in conditions like myasthenia gravis typically appears within 1-2 weeks. Full therapeutic effects may take 4-6 weeks to develop as inflammation subsides and tissue repair occurs.
Zilucoplan is a synthetic macrocyclic peptide given subcutaneously, while eculizumab is a monoclonal antibody requiring intravenous infusion. Both inhibit complement C5 but zilucoplan offers more convenient self-administration and better tissue penetration due to its smaller size.
Research protocols often combine zilucoplan with existing treatments, but this increases infection risk. Any combination requires careful monitoring and may necessitate dose adjustments of concurrent medications. Vaccination status must be current before starting.
Complement inhibition increases risk of infections with encapsulated bacteria, particularly Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. Meningococcal vaccination is essential before treatment, with pneumococcal and Hib vaccines also recommended.
Store refrigerated at 2-8°C and allow to warm to room temperature before injection. Administer subcutaneously, rotating injection sites to prevent lipodystrophy. Pre-filled pens or syringes enable self-administration after proper training.
Abrupt discontinuation can cause complement-mediated disease flares as C5 inhibition ends. Symptoms may return within days to weeks depending on the underlying condition. Gradual tapering under medical supervision is recommended when stopping therapy.
Regular monitoring includes complement activity tests (CH50), complete blood counts, liver function tests, and infection screening. Baseline and periodic assessment for anti-drug antibodies may be performed in research settings.
Serious hypersensitivity reactions are rare but possible. Mild injection site reactions are more common. Any signs of systemic allergic reaction (rash, breathing difficulty, swelling) require immediate medical attention and treatment discontinuation.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.